Review Paper<br>B cell depletion with monoclonal antibody as treatment for rheumatoid arthritis

Piotr Wiland

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2006
vol. 44

Send email

Copy url:

abstract:

Review Paper
B cell depletion with monoclonal antibody as treatment for rheumatoid arthritis

Piotr Wiland

RU 2006; 44, 3: 162–168

Online publish date: 2006/06/26

View full text Get citation

In recent years our knowledge of the role of B lymphocytes in the pathogenesis of rheumatoid arthritis (RA) has expanded and it is now thought that B cells have a more extensive role than was previously appreciated. They seem to play a pivotal role in the activation of synovial T cells and induction of cytokine secretion. CD20 antigen expressed on the surface of B cells is highly specific to B cells. The success of B cell depletion therapy by using the monoclonal antibody Rituximab, which targets CD20, further emphasized the importance of B cells in the pathogenesis of RA.

keywords:

rheumatoid arthritis, lymphocyte B, rituximab, CD20 antigen

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Review PaperB cell depletion with monoclonal antibody as treatment for rheumatoid arthritis

Piotr Wiland

rheumatoid arthritis, lymphocyte B, rituximab, CD20 antigen

Review Paper
B cell depletion with monoclonal antibody as treatment for rheumatoid arthritis